Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Toronto

$150,000.00

Examining GLP-1 peptides as a novel cardioprotective agent for pediatric cardiovascular surgery

EF 2022-23

Résumé
Supervisors: Dr. Mansoor Husain and Dr. Osami Honjo, University of Toronto Heart failure (HF) is a growing medical problem, currently affecting over 1 million Canadians, and a leading driver of morbidity, mortality and health care costs. HF occurs when damaged hearts no longer meet the body's demands. There is no cure for HF, and there is a pressing clinical need to prevent HF in babies and children born with heart structure defects. These small children will progress to HF if their heart structure is not surgically corrected. However, these patients often need very complex surgeries, or repeated surgeries, where the heart has to be stopped for long periods of time to allow surgical repair. Currently, surgeons use "cardioplegia" infusions to temporarily stop and protect the heart during repair. However, cardioplegia solutions are not uniformly standardized or optimized, and hence heart damage during surgery is the leading cause of death following otherwise successful cardiac surgery in children. My project aims to provide new treatment options and improve outcomes for this particularly vulnerable patient population. I will do this by developing a pre-clinical piglet model of prolonged heart surgery. With this model, I will characterize the exact pathways of heart damage in this setting which is key to understanding how to correct the problem. Based on what we know about heart damage in similar settings, we believe the key pathways involve metabolism, oxidative stress and inflammation. We have discovered that a derivative of the naturally occurring gut-hormone glucagon-like peptide-1 (GLP-1), called GLP-1(28-36), protects against similar types of heart damage in mouse models. As such, I will also test if GLP-1(28-36) protects the heart in our piglet model of heart surgery. This work will improve our understanding of pediatric heart surgery and potentially bring our promising GLP-1(28-36) approach to clinical medicine.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
474427
Name
Lao Robert X
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Examining GLP-1 peptides as a novel cardioprotective agent for pediatric cardiovascular surgery
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Heart Failure; Myocardial Protection; Pediatric Heart Surgery
Abstract
Supervisors: Dr. Mansoor Husain and Dr. Osami Honjo, University of Toronto Heart failure (HF) is a growing medical problem, currently affecting over 1 million Canadians, and a leading driver of morbidity, mortality and health care costs. HF occurs when damaged hearts no longer meet the body's demands. There is no cure for HF, and there is a pressing clinical need to prevent HF in babies and children born with heart structure defects. These small children will progress to HF if their heart structure is not surgically corrected. However, these patients often need very complex surgeries, or repeated surgeries, where the heart has to be stopped for long periods of time to allow surgical repair. Currently, surgeons use "cardioplegia" infusions to temporarily stop and protect the heart during repair. However, cardioplegia solutions are not uniformly standardized or optimized, and hence heart damage during surgery is the leading cause of death following otherwise successful cardiac surgery in children. My project aims to provide new treatment options and improve outcomes for this particularly vulnerable patient population. I will do this by developing a pre-clinical piglet model of prolonged heart surgery. With this model, I will characterize the exact pathways of heart damage in this setting which is key to understanding how to correct the problem. Based on what we know about heart damage in similar settings, we believe the key pathways involve metabolism, oxidative stress and inflammation. We have discovered that a derivative of the naturally occurring gut-hormone glucagon-like peptide-1 (GLP-1), called GLP-1(28-36), protects against similar types of heart damage in mouse models. As such, I will also test if GLP-1(28-36) protects the heart in our piglet model of heart surgery. This work will improve our understanding of pediatric heart surgery and potentially bring our promising GLP-1(28-36) approach to clinical medicine.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Lao, Robert X
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~